MedPath

Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China

Recruiting
Conditions
Non-Segmental Vitiligo
Registration Number
NCT07058051
Lead Sponsor
AbbVie
Brief Summary

The purpose of this study is to evaluate the patterns of treatment, healthcare resources utilized and the burdens associated with non-segmental vitiligo (NSV) amongst participants in China

This study is a cross-sectional, multicenter, observational study of vitiligo patients in China. The cross-sectional design is sufficient to characterize the overall current burden of NSV.

Detailed Description

Cross-Sectional

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Male and female patients, age ≥ 12.
  • Chinese patients meet the diagnosis of Non-Segmental Vitiligo (NSV) and 5≤ Total Vitiligo Area Scoring Index (T-VASI<50) with or without facial involvement.
  • Medical history available within the last 6 months.
  • Ability to understand the questionnaires, with parental support as required for adolescents (between ≥ 12 and < 18 years of age at inclusion visit).
  • Willing to provide a patient authorization form to use and disclose personal health information (or informed consent, where applicable) to participate in the study; for adolescent subjects, authorization and/or consent will be provided by a parent or legal guardian, where applicable.
Exclusion Criteria
  • Unable or unwilling to comply with study requirements and electronic Patient-Reported Outcome (ePRO) collection.
  • Segmental or localized vitiligo.
  • Greater than 33% leukotrichia in areas of vitiligo on the face or on the body.
  • History of active skin disease other than vitiligo that could interfere with the assessment of vitiligo.
  • Patients who are participating in interventional clinical trial(s) at time of study visit.
  • Patients who are currently receiving treatment with any investigational drug/device/intervention or have received any investigational product within 1 month or 5 half-lives of the investigational agent (whichever is longer) prior to enrollment.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Total Vitiligo Area Scoring Index (T-VASI)At Inclusion Visit (Day 1)

The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100, with higher scores indicating more severe disease.

Vitiligo Quality of Life Scale (VitiQoL)At Inclusion Visit (Day 1)

The VitiQoL is an 16-item instrument assessing impact of vitiligo on quality of life. 15 items are scored on a 7-point Likert scale, ranging from "not at all" to "all the time". An additional item (not contributing to total score) assesses current severity of condition on a 7-point scale ranging from "no skin involvement" to "most severe case"

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Shandong Dermatological Hospital /ID# 276918

🇨🇳

Jinan, Shandong, China

Shandong Dermatological Hospital /ID# 276918
🇨🇳Jinan, Shandong, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.